Herve Gisserot, general manager for GSK China, poses for a photograph in front of a company logo during an interview with Reuters at an office in Shanghai, China, November 25, 2015. GlaxoSmithKline Plc has cut 40 percent of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record 490 million fine in 2014. Picture taken November 25. To match Interview GSK-CHINA/ REUTERS/Ben Hirschler
SHANGHAI: GlaxoSmithKline Plc (GSK) has cut 40% of its sales reps in China and axed some units as it eyes a return to growth in 2016, after sales plunged during a bribery scandal that landed it with a record US$490mil fine in 2014.
The British firm is gambling on a new, cleaner image to reboot its performance and reputation with doctors and consumers, China head Herve Gisserot (pic) told Reuters during a wide-ranging interview at the group’s Shanghai headquarters.
Limited time offer:
Just RM5 per month.
